These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33044357)

  • 21. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size calculations for randomized controlled trials.
    Wittes J
    Epidemiol Rev; 2002; 24(1):39-53. PubMed ID: 12119854
    [No Abstract]   [Full Text] [Related]  

  • 23. Is Propensity Score Analysis a Valid Surrogate of Randomization for the Avoidance of Allocation Bias?
    Torres F; Ríos J; Saez-Peñataro J; Pontes C
    Semin Liver Dis; 2017 Aug; 37(3):275-286. PubMed ID: 28847037
    [No Abstract]   [Full Text] [Related]  

  • 24. Alternatives to Randomised Controlled Trials for the Poor, the Impatient, and When Evaluating Emerging Technologies.
    Mani K; Björck M
    Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):598-599. PubMed ID: 30509892
    [No Abstract]   [Full Text] [Related]  

  • 25. Statistics Commentary Series: Commentary #10-Dealing With Drop-Outs.
    Streiner DL
    J Clin Psychopharmacol; 2015 Oct; 35(5):496-8. PubMed ID: 25803367
    [No Abstract]   [Full Text] [Related]  

  • 26. Statistics commentary series: Commentary #5--can it work or does it work? The difference between efficacy and effectiveness trials.
    Streiner DL
    J Clin Psychopharmacol; 2014 Dec; 34(6):672-4. PubMed ID: 25275674
    [No Abstract]   [Full Text] [Related]  

  • 27. Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'.
    Kranke P
    Anaesthesia; 2012 Oct; 67(10):1063-7. PubMed ID: 22897144
    [No Abstract]   [Full Text] [Related]  

  • 28. Design optimization for dose-finding trials: a review.
    Aouni J; Bacro JN; Toulemonde G; Colin P; Darchy L; Sebastien B
    J Biopharm Stat; 2020 Jul; 30(4):662-673. PubMed ID: 32183578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines.
    Bittl JA; He Y
    Circ Cardiovasc Qual Outcomes; 2017 Aug; 10(8):. PubMed ID: 28798016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Learning From Major Clinical Trials: Bending Without Breaking.
    Pfeffer MA
    Circulation; 2017 Dec; 136(23):2207-2209. PubMed ID: 29203564
    [No Abstract]   [Full Text] [Related]  

  • 31. University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (afternoon panel session).
    Little RJ; Tchetgen EJT; Troxel AB
    Clin Trials; 2019 Aug; 16(4):381-390. PubMed ID: 31244326
    [No Abstract]   [Full Text] [Related]  

  • 32. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Getting maximum information out of a continuous outcome: applying linear regression.
    de Ridder MA; de Vries T; Arends LR
    EuroIntervention; 2015 Oct; 11(6):718-22. PubMed ID: 26499224
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical trials methodology: randomization, intent-to-treat, and random-effects regression.
    Atkins DC
    Depress Anxiety; 2009; 26(8):697-700. PubMed ID: 19658122
    [No Abstract]   [Full Text] [Related]  

  • 35. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 37. Undue reliance on I(2) in assessing heterogeneity may mislead.
    Rücker G; Schwarzer G; Carpenter JR; Schumacher M
    BMC Med Res Methodol; 2008 Nov; 8():79. PubMed ID: 19036172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates.
    Zimmermann G; Kieser M; Bathke AC
    J Biopharm Stat; 2020; 30(1):143-159. PubMed ID: 31327284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensions to the two-stage randomized trial design for testing treatment, self-selection, and treatment preference effects to binary outcomes.
    Cameron B; Peduzzi P; Esserman D
    Stat Med; 2018 Sep; 37(22):3147-3178. PubMed ID: 29855065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Missing data in rheumatologic studies and the practical reality of modern approaches to the analysis of incomplete subject data: comment on the article by Baron et al and the editorial by Boers.
    Steele R; Hudson M
    Arthritis Rheum; 2008 Sep; 59(9):1367-8. PubMed ID: 18759312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.